Αποτελέσματα Αναζήτησης
4 Ιαν 2023 · Sunlenca is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV-1. Sunlenca works by blocking the HIV-1 virus’ protein shell (the capsid), thereby interfering with multiple essential steps of the viral lifecycle.
16 Ιουλ 2021 · These guidelines bring in the most recent guidance on HIV testing strategies - the entry point for HIV prevention and treatment - and include comprehensive guidance on infant diagnosis. Key recommendations are presented on rapid antiretroviral therapy (ART) initiation and the use of dolutegravir.
11 Δεκ 2023 · Using drug therapy to block transmission and prevent HIV, HIV pre-exposure prophylaxis (PrEP) provides a critical intervention to reduce community spread and protect those with reasons to utilize PrEP.
27 Ιαν 2021 · This is the first FDA-approved injectable, complete regimen for HIV-1 infected adults that is administered once a month.
22 Ιαν 2021 · [Yesterday] the U.S. Food and Drug Administration approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace a current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral ...
Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms...
16 Αυγ 2024 · New technologies for therapeutic delivery are transforming health care for a range of conditions, including HIV. These advances allow for new medications, altered formulations of existing drugs, new drugs with a longer duration between dosing (weekly, once every month and 2 months and 6 months, and potentially even annually), and various ...
